RESEARCH-USE BIOSIMILAR ANTIBODY
Benralizumab
Monoclonal antibody · IgG1
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
TARGETIL5
YMonoclonal antibody
CATALOGSC-BS-730
CATALOG NUMBERSC-BS-730
MOLECULAR WEIGHTApprox. 146.06 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
Benralizumab is a recombinant research-use antibody directed against IL5.